(Q36458793)

English

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status (English)

1 reference

Europe PubMed Central

14 August 2017

1 reference

based on heuristic

inferred from title

Diethelm Wallwiener

6

object named as

Diethelm Wallwiener

0 references

1

object named as

Tanja Fehm

0 references

9

object named as

Jonathan Uhr

1 reference

Europe PubMed Central

14 August 2017

author name string

Sven Becker

2

1 reference

Europe PubMed Central

14 August 2017

Silke Duerr-Stoerzer

3

1 reference

Europe PubMed Central

14 August 2017

Karl Sotlar

4

1 reference

Europe PubMed Central

14 August 2017

Volkmar Mueller

5

1 reference

Europe PubMed Central

14 August 2017

Erich Solomayer

8

1 reference

Europe PubMed Central

14 August 2017

Nancy Lane

7

1 reference

Europe PubMed Central

14 August 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

14 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

14 August 2017

9

1 reference

Europe PubMed Central

14 August 2017

5

1 reference

Europe PubMed Central

14 August 2017

R74

1 reference

Europe PubMed Central

14 August 2017

https://scigraph.springernature.com/pub.10.1186/bcr1783

0 references

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Serum HER-2/neu in the management of breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

30 September 2017

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

28 June 2018

Quantitation of cell shedding into efferent blood of mammary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

28 June 2018

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

erbB-2 (HER-2) and breast cancer progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2242672

21 September 2018

Is circulating HER-2 more than just a tumor marker?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change of HER-2/neu status in a subset of distant metastases from breast carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes of serum HER2 status during clinical course of metastatic breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17963511

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR1783

1 reference

Europe PubMed Central

14 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36458793&oldid=2069408659"